Deplatt a 150

Deplatt a 150

Reading File

Deplatt A 150 is a combination antiplatelet tablet containing Aspirin 150 mg + Clopidogrel 75 mg. It is used to prevent blood clots in conditions like acute coronary syndrome, recent heart attack, or stroke.

Searching sources...

Finding Sources

Searching PubMed

clopidogrel aspirin dual antiplatelet therapy

Searching the Web

Deplatt A 150 clopidogrel aspirin uses dosage indications

Reading File

Deplatt A 150 is a fixed-dose combination tablet manufactured by Torrent Pharmaceuticals containing:

Clopidogrel 75 mg + Aspirin 150 mg

Composition & Mechanism

Component	Class	Mechanism
Clopidogrel 75 mg	P2Y12 receptor antagonist (thienopyridine)	Irreversibly blocks ADP receptors on platelets, inhibiting ADP-mediated platelet aggregation
Aspirin 150 mg	COX-1 inhibitor (NSAID)	Irreversibly inhibits cyclooxygenase-1, preventing thromboxane A2 synthesis and platelet aggregation

Together, they block two separate platelet activation pathways, producing synergistic antiplatelet effect - this is called Dual Antiplatelet Therapy (DAPT).

Indications

Acute Coronary Syndrome (ACS) - unstable angina, NSTEMI, STEMI
Post-Percutaneous Coronary Intervention (PCI) - after coronary stenting (bare-metal or drug-eluting stents)
Recent Myocardial Infarction (MI)
Recent Ischemic Stroke or TIA (in selected cases)
Peripheral Arterial Disease (PAD) with high atherothrombotic risk
Prevention of in-stent restenosis after PCI

Dosage

Usual adult dose: 1 tablet once daily (Clopidogrel 75 mg + Aspirin 150 mg)
Best taken with food to reduce GI side effects
Loading dose (in ACS): Clopidogrel 300-600 mg + Aspirin 300 mg is given first, then maintenance with Deplatt A 150 once daily

Duration of Therapy (DAPT)

Clinical Scenario	Minimum DAPT Duration
Bare-metal stent (BMS)	3-4 weeks
Drug-eluting stent (DES)	Minimum 12 months
ACS (medically managed)	12 months
Recent MI or stroke	As directed by physician

Textbook of Family Medicine 9e, p. 3771: "For patients receiving a drug-eluting stent, dual antiplatelet therapy needs to be continued for a minimum of 1 year."

Side Effects

Common:

GI upset, dyspepsia, nausea
Abdominal pain, heartburn
Diarrhea

Serious:

Bleeding - GI bleeding, intracranial bleed (most important risk)
Thrombotic Thrombocytopenic Purpura (TTP) - rare, with clopidogrel
Neutropenia - rare
Hypersensitivity/skin rash

Contraindications

Active pathological bleeding (peptic ulcer, intracranial hemorrhage)
Hypersensitivity to aspirin or clopidogrel
Severe hepatic impairment
Third trimester of pregnancy

Important Drug Interactions

Drug	Interaction
PPIs (especially omeprazole)	Omeprazole reduces clopidogrel efficacy (CYP2C19 inhibition); prefer pantoprazole if GI protection needed
NSAIDs	Increased bleeding risk
Warfarin/anticoagulants	Greatly increased bleeding risk; use only if clearly indicated
SSRIs/SNRIs	Increased GI bleed risk

Clinical Notes

Clopidogrel resistance occurs in ~25-30% of patients due to CYP2C19 genetic polymorphism (poor metabolizers) - these patients may benefit from prasugrel or ticagrelor instead
Do not abruptly stop DAPT (especially post-stenting) - risk of stent thrombosis
Use pantoprazole (not omeprazole) for GI protection alongside DAPT
A 2025 Lancet meta-analysis (PMID 40902613) found clopidogrel monotherapy vs aspirin for secondary coronary prevention - still confirming clopidogrel's role; combination DAPT remains standard post-ACS/PCI
A 2024 JAMA Cardiology network meta-analysis (PMID 39382876) supports short-duration DAPT after DES in ACS patients as a reasonable strategy to balance ischemic and bleeding risk

Summary

Deplatt A 150 is a standard DAPT combination used to prevent recurrent cardiovascular events. The aspirin 150 mg dose is the standard maintenance dose used in India (globally, 75-100 mg is more common). It should always be taken under medical supervision with attention to bleeding risk, GI protection, and appropriate duration based on the clinical indication.

This is a shared conversation. Sign in to Orris to start your own chat.